Consensus Xylem Inc.

Equities

XYL

US98419M1009

Market Closed - Nyse 04:00:02 2024-06-07 pm EDT 5-day change 1st Jan Change
137.3 USD +0.33% Intraday chart for Xylem Inc. -2.62% +20.08%

Evolution of the average Target Price on Xylem Inc.

Price target over the last 5 years

History of analyst recommendation changes

f9f6d43d29f04917adad038548a8f2.vcfr4P9exyEQKECFi1EnbuwkgRUVxcskKEbBi5P6ADs.-KyEk701lUtienHXyQZJGN1d61ciiINnHSz0zf_NRXbzr7qsiS-TGHxDFQ~3c95cf273515c332f6605228fcd2fcdf
Xylem Insider Sold Shares Worth $3,030,387, According to a Recent SEC Filing MT
TD Cowen Adjusts Xylem Price Target to $138 From $135, Keeps Buy Rating MT
Redburn Atlantic Adjusts Price Target on Xylem to $160 From $157 MT
BNP Paribas Exane Adjusts Price Target on Xylem to $168 From $160, Keeps Outperform Rating MT
Goldman Sachs Adjusts Price Target on Xylem to $159 From $155 MT
Oppenheimer Adjusts Price Target on Xylem to $152 From $147 MT
Stifel Adjusts Price Target on Xylem to $157 From $150 MT
Argus Adjusts Price Target on Xylem to $165 From $146 MT
Wolfe Research Adjusts Price Target on Xylem to $163 From $153 MT
Redburn Atlantic Adjusts Price Target on Xylem to $157 From $148, Keeps Buy Rating MT
Citigroup Adjusts Price Target on Xylem to $141 From $139 MT
Deutsche Bank Adjusts Price Target on Xylem to $152 From $146 MT
Goldman Sachs Adjusts Price Target on Xylem to $155 From $150 MT
Wolfe Adjusts Price Target on Xylem to $153 From $145 MT
RBC Capital Adjusts Price Target on Xylem to $162 From $157 MT
Oppenheimer Adjusts Xylem Price Target to $147 From $142, Maintains Outperform Rating MT
BNP Paribas Exane Adjusts Price Target on Xylem to $160 From $150 MT
Jefferies Adjusts Price Target on Xylem to $130 From $120 MT
ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna... Our Logo
Baird Adjusts Xylem Price Target to $155 From $151 MT
Melius Research Raises Xylem's Price Target to $128 From $127 MT
Wolfe Adjusts Price Target on Xylem to $145 From $143 MT
RBC Capital Adjusts Xylem Price Target to $157 From $153 MT
Oppenheimer Adjusts Price Target on Xylem to $142 From $133, Outperform Rating Kept MT
BNP Paribas Exane Starts Xylem With Outperform Rating, $150 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
137.3 USD
Average target price
147.9 USD
Spread / Average Target
+7.74%
High Price Target
168 USD
Spread / Highest target
+22.34%
Low Price Target
112 USD
Spread / Lowest Target
-18.44%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Xylem Inc.

TD Cowen
Redburn Atlantic
BNP Paribas Exane
Goldman Sachs
Oppenheimer
Stifel Nicolaus
Argus
Wolfe Research
Citigroup
Deutsche Bank Securities
RBC Capital Markets
Jefferies & Co.
Baird
Melius Research
Seaport Global Securities
Cowen
Morgan Stanley
Mizuho Securities
Raymond James
Atlantic Equities
Credit Suisse
Berenberg Bank
Loop Capital
Rosenblatt Securities
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings